Halozyme Therapeutics shares rose 2.6% this afternoon to a price of $72.5. The stock is still trading within range of its average target price of $74.56, and over the last 52 weeks, it has recorded a 30.9% performance. Analysts have given the Mid-Cap Biotechnology stock target prices ranging from $54.0 to $92.0 dollars per share, with an average rating of buy.
The stock has an above average percentage of its shares sold short at 13.4%, and a short ratio of 5.86. Since 1.16% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 100.4% of Halozyme Therapeutics's shares being owned by this investor type.
Institutions Invested in Halozyme Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-09-30 | Blackrock Inc. | 11% | 12,860,199 | $932,300,161 |
| 2025-09-30 | Vanguard Group Inc | 10% | 11,629,786 | $843,101,368 |
| 2025-06-30 | State Street Corporation | 5% | 5,935,045 | $430,261,103 |
| 2025-06-30 | Invesco Ltd. | 3% | 3,465,889 | $251,259,632 |
| 2025-09-30 | Snyder Capital Management, LP | 2% | 2,733,844 | $198,190,028 |
| 2025-06-30 | Arrowstreet Capital, Limited Partnership | 2% | 2,541,181 | $184,222,923 |
| 2025-06-30 | Alliancebernstein L.P. | 2% | 2,455,268 | $177,994,660 |
| 2025-09-30 | Geode Capital Management, LLC | 2% | 2,431,279 | $176,255,577 |
| 2025-06-30 | Macquarie Group Limited | 2% | 2,083,392 | $151,035,508 |
| 2025-09-30 | Dimensional Fund Advisors LP | 2% | 2,078,426 | $150,675,498 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Halozyme Therapeutics.
